Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:DARE NASDAQ:GNPX NASDAQ:HOWL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.23-1.2%$1.34$1.01▼$8.08$33.17M0.311.27 million shs176,835 shsDAREDare Bioscience$2.70-7.4%$1.87$1.27▼$9.19$39.24M1.09374,010 shs332,951 shsGNPXGenprex$0.86-0.2%$1.56$0.85▼$55.00$8.98M-0.941.04 million shs140,068 shsHOWLWerewolf Therapeutics$0.69+11.6%$0.81$0.53▼$2.38$33.44M0.41425,021 shs1.76 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-4.62%+0.81%+13.76%-17.33%-18.95%DAREDare Bioscience-7.91%+27.63%+64.41%+72.19%+0.66%GNPXGenprex-2.84%-11.28%-36.86%-60.68%-93.82%HOWLWerewolf Therapeutics-4.64%-13.84%-38.00%+1.27%-32.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.23-1.2%$1.34$1.01▼$8.08$33.17M0.311.27 million shs176,835 shsDAREDare Bioscience$2.70-7.4%$1.87$1.27▼$9.19$39.24M1.09374,010 shs332,951 shsGNPXGenprex$0.86-0.2%$1.56$0.85▼$55.00$8.98M-0.941.04 million shs140,068 shsHOWLWerewolf Therapeutics$0.69+11.6%$0.81$0.53▼$2.38$33.44M0.41425,021 shs1.76 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-4.62%+0.81%+13.76%-17.33%-18.95%DAREDare Bioscience-7.91%+27.63%+64.41%+72.19%+0.66%GNPXGenprex-2.84%-11.28%-36.86%-60.68%-93.82%HOWLWerewolf Therapeutics-4.64%-13.84%-38.00%+1.27%-32.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.25Hold$11.00797.96% UpsideDAREDare Bioscience 2.33Hold$10.00271.06% UpsideGNPXGenprex 1.00SellN/AN/AHOWLWerewolf Therapeutics 2.14Hold$3.75441.91% UpsideCurrent Analyst Ratings BreakdownLatest GNPX, DARE, HOWL, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BTAIBioXcel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026DAREDare Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026BTAIBioXcel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $5.003/17/2026BTAIBioXcel Therapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$17.003/9/2026BTAIBioXcel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/5/2026BTAIBioXcel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$640K51.83N/AN/A($4.37) per share-0.28DAREDare Bioscience$1.03M38.09N/AN/A$0.20 per share13.48GNPXGenprexN/AN/AN/AN/A$2.42 per shareN/AHOWLWerewolf Therapeutics$1.88M17.89N/AN/A$0.51 per share1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$69.90M-$6.71N/AN/AN/A-10,887.38%N/A-181.48%5/11/2026 (Estimated)DAREDare Bioscience-$13.40M-$1.25N/AN/AN/AN/AN/A-56.52%5/12/2026 (Estimated)GNPXGenprex-$16.23M-$26.50N/AN/AN/AN/A-464.05%-275.54%6/3/2026 (Estimated)HOWLWerewolf Therapeutics-$60.82M-$1.36N/AN/AN/AN/A-158.82%-69.75%N/ALatest GNPX, DARE, HOWL, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026DAREDare Bioscience-$0.33N/AN/AN/A$0.03 millionN/A5/11/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325N/AN/AN/A$0.39 millionN/A5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A3/27/2026Q4 2025BTAIBioXcel Therapeutics-$0.58-$0.58N/A$0.65$0.15 millionN/A3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/A3/26/2026Q4 2025DAREDare Bioscience-$0.44-$0.02+$0.42-$0.02$0.75 million$1.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A0.830.82DAREDare BioscienceN/A1.141.14GNPXGenprexN/A3.843.84HOWLWerewolf TherapeuticsN/A1.621.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%DAREDare Bioscience6.70%GNPXGenprex14.05%HOWLWerewolf Therapeutics64.84%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics3.70%DAREDare Bioscience4.80%GNPXGenprex0.44%HOWLWerewolf Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics9027.08 million26.07 millionNo DataDAREDare Bioscience3014.56 million13.86 millionNot OptionableGNPXGenprex2010.42 million10.37 millionNo DataHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableGNPX, DARE, HOWL, and BTAI HeadlinesRecent News About These CompaniesWerewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 79,086 Shares4 hours ago | insidertrades.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Rating of "Hold" from AnalystsMay 8 at 3:57 AM | americanbankingnews.comWerewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7 at 4:05 PM | globenewswire.comLuke Evnin Sells 58,394 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockMay 6 at 5:56 AM | americanbankingnews.comLuke Evnin Sells 47,963 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockMay 6 at 5:56 AM | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) Director Sells $34,533.36 in StockMay 5 at 5:23 AM | insidertrades.comWerewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 168,262 SharesMay 5 at 4:57 AM | americanbankingnews.comInsider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 56,559 Shares of StockApril 30, 2026 | insidertrades.comWerewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14April 28, 2026 | msn.comWerewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid PriceMarch 28, 2026 | tipranks.comWerewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38March 27, 2026 | msn.comWerewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 27, 2026 | globenewswire.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Announces Plan to Explore Strategic AlternativesFebruary 26, 2026 | finanznachrichten.deWerewolf Therapeutics Announces Plan to Explore Strategic AlternativesFebruary 24, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Medtronic (MDT), Elanco Animal Health (ELAN) and Werewolf Therapeutics (HOWL)February 18, 2026 | theglobeandmail.comWerewolf Therapeutics stock falls after announcing 64% workforce reductionFebruary 13, 2026 | investing.comWerewolf Therapeutics stock rises over 5% after hours on workforce reduction, including executivesFebruary 13, 2026 | msn.comWerewolf Therapeutics Receives Nasdaq Minimum Bid Price NoticeFebruary 6, 2026 | tipranks.comLuke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockJanuary 21, 2026 | insidertrades.comLuke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockJanuary 16, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, DARE, HOWL, and BTAI Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$1.23 -0.02 (-1.21%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Dare Bioscience NASDAQ:DARE$2.70 -0.22 (-7.39%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Genprex NASDAQ:GNPX$0.86 0.00 (-0.23%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Werewolf Therapeutics NASDAQ:HOWL$0.69 +0.07 (+11.61%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
